Law Clinic Currents, vol. 2 no. 2

A Publication of the Environmental Law and Justice Clinic and the Women\u27s Employment Rights Clinic

Law Clinic Currents, vol. 2 no. 1

A Publication of the Environmental Law and Justice Clinic and the Women\u27s Employment Rights Clinic

Fall 2018 Experiential Courses Information Sessions

Interested in applying for a Fall Clinic? Come to the Clinic Fair to speak with students and faculty about their experiences.https://larc.cardozo.yu.edu/flyers-2017-2018/1061/thumbnail.jp

Clinical Perspectives: Fall 2013

https://scholarship.law.gwu.edu/clinical_perspectives/1004/thumbnail.jp

Clinical Perspectives: Spring 2011

https://scholarship.law.gwu.edu/clinical_perspectives/1001/thumbnail.jp

Clinical Perspectives: Spring 2011

https://scholarship.law.gwu.edu/clinical_perspectives/1001/thumbnail.jp

Clinical Perspectives: Spring 2009

https://scholarship.law.gwu.edu/clinical_perspectives/1003/thumbnail.jp

Clinical Perspectives: Fall 2013

https://scholarship.law.gwu.edu/clinical_perspectives/1004/thumbnail.jp

Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves. insights from the nationwide plectrum study

Vitamin K antagonists are indicated for the thromboprophylaxis in patients with mechanical prosthetic heart valves (MPHV). However, it is unclear whether some differences between acenocoumarol and warfarin in terms of anticoagulation quality do exist. We included 2111 MPHV patients included in the nationwide PLECTRUM registry. We evaluated anticoagulation quality by the time in therapeutic range (TiTR). Factors associated with acenocoumarol use and with low TiTR were investigated by multivariable logistic regression analysis. Mean age was 56.8 ± 12.3 years; 44.6% of patients were women and 395 patients were on acenocoumarol. A multivariable logistic regression analysis showed that patients on acenocoumarol had more comorbidities (i.e., ≥3, odds ratio (OR) 1.443, 95% confidence interval (CI) 1.081-1.927, p = 0.013). The mean TiTR was lower in the acenocoumarol than in the warfarin group (56.1 ± 19.2% vs. 61.6 ± 19.4%, p < 0.001). A higher prevalence of TiTR (<60%, <65%, or <70%) was found in acenocoumarol users than in warfarin ones (p < 0.001 for all comparisons). Acenocoumarol use was associated with low TiTR regardless of the cutoff used at multivariable analysis. A lower TiTR on acenocoumarol was found in all subgroups of patients analyzed according to sex, hypertension, diabetes, age, valve site, atrial fibrillation, and INR range. In conclusion, anticoagulation quality was consistently lower in MPHV patients on acenocoumarol compared to those on warfarin

Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus:Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort

BackgroundWe aimed to identify factors associated with a significant reduction in SLE disease activity over 12 months assessed by the BILAG Index.MethodsIn an international SLE cohort, we studied patients from their 'inception enrolment' visit. We also defined an 'active disease' cohort of patients who had active disease similar to that needed for enrolment into clinical trials. Outcomes at 12 months were; Major Clinical Response (MCR: reduction to classic BILAG C in all domains, steroid dose of ≤7.5 mg and SLEDAI ≤ 4) and 'Improvement' (reduction to ≤1B score in previously active organs; no new BILAG A/B; stable or reduced steroid dose; no increase in SLEDAI). Univariate and multivariate logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) and cross-validation in randomly split samples were used to build prediction models.Results'Inception enrolment' (n = 1492) and 'active disease' (n = 924) patients were studied. Models for MCR performed well (ROC AUC = .777 and .732 in the inception enrolment and active disease cohorts, respectively). Models for Improvement performed poorly (ROC AUC = .574 in the active disease cohort). MCR in both cohorts was associated with anti-malarial use and inversely associated with active disease at baseline (BILAG or SLEDAI) scores, BILAG haematological A/B scores, higher steroid dose and immunosuppressive use.ConclusionBaseline predictors of response in SLE can help identify patients in clinic who are less likely to respond to standard therapy. They are also important as stratification factors when designing clinical trials in order to better standardize overall usual care response rates